icon-folder.gif   Conference Reports for NATAP  
  5th IAS Conference on HIV Pathogenesis, Treatment and Prevention
July 19th-22nd 2009
Capetown, South Africa
Back grey_arrow_rt.gif
Maraviroc IAS Reports: MERIT (naives), Genotype vs Tropism (MOTIVATE), Malignancies Report (MOTIVATE)
  Virologic Suppression on Maraviroc in Treatment-Naive Patients With R5 HIV-1 is Similar to Efavirenz at High Baseline Viral Load, and Maraviroc Discontinuations for Adverse Events are Less Likely to Show Drug Resistance: 48-Week Results From the MERIT Study - (08/01/09)
The MERIT Study of Maraviroc in Antiretroviral-Naive Patients With R5 HIV-1: 96-Week Results - (07/21/09)
96-Week Merit Es Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naive HIV Patients; Results Consistent With 48-Week Analysis - Pfizer press release - (07/21/09)
Screening for HIV Tropism using Population-based V3 Genotypic Analysis: a Retrospective Virologic Outcome Analysis Using Stored Plasma Screening Samples from the MOTIVATE Studies of Maraviroc in Treatment Experienced Patients - (07/23/09)
Incidence and Risk Factors for Malignancies in Treatment-experienced (TE) Patients in the MOTIVATE Studies of Maraviroc (MVC) + Optimized Background Therapy (OBT): 96-Week Follow-up - (07/22/09)